Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BIIB

3 Stocks to Buy This Month if You Haven’t Already

Although the stock market has seen a decline in inflation for October, it is far from the Fed’s target, and rate hikes might continue. However, the anticipation of a strong stock market rebound in 2023 is rising. So, we think it could be wise to load up on fundamentally sound…

StockNews.com

2 Stocks You Could Keep in Your Portfolio Forever

Despite signs of inflation cooling in the United States, the IMF is not expecting the global economic picture to improve anytime soon. However, the cooling inflation might induce the Fed to ease the pace of rate hikes. As economic uncertainties remain, we think fundamentally solid stocks McDonald’s (MCD) and Biogen…

StockNews.com

The 4 Best Stocks to Buy This November

Favorable inflation data for October has raised the odds of slower federal rate hikes ahead. The market has been celebrating the inflation report, and experts believe the current rally could sustain for a while. Therefore, investors could buy quality stocks such as Gilead Sciences (GILD), Biogen (BIIB), Hillenbrand (HI), and…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Stocks to Buy Now for a Sound Investment Portfolio

October inflation report came in lower than estimates, indicating cooling inflationary pressures. Moreover, the market could soon be up for a significant rally as per historical trends. Given the backdrop, it could be wise to buy stocks of fundamentally sound companies, Coca-Cola (KO), Biogen (BIIB), and Sisecam Resources (SIRE), to…

StockNews.com

4 Stocks You Can Purchase at a Discount in Q4

Aggressive monetary policy tightening by the Fed and red-hot inflation have led to a broad stock market sell-off this year. However, the Fed is expected to slow the pace of rate hikes in the coming months. Therefore, it could be the right time to invest in fundamentally solid stocks Oracle…

StockNews.com

4 Nasdaq Stocks You'll Never Regret Buying

Amid the Fed's consecutive rate hikes, the Nasdaq composite has lost more than 30% year-to-date. However, it has gained marginally over the past month. Moreover, the Fed is expected to slow down the pace of rate hikes in the upcoming terms. Therefore, we think investors could consider buying quality Nasdaq…

StockNews.com

3 Strong Buy Stocks Begging to Be Bought in Q4

The Federal Reserve announced its fourth consecutive 75-bps rate hike yesterday. As the chances of the economy falling into a recession are tightening, fundamentally strong and resilient stocks Merck & Co (MRK), Biogen (BIIB), and Kroger (KR), which are rated Strong Buy in our proprietary rating system, could be safe…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

2 Trending Stocks on Wall Street to Buy Right Now

Despite fears of another major interest rate hike by the Fed in response to the stubborn inflation data for September, stocks such as Microsoft (MSFT) and Biogen (BIIB) have shown remarkable stability. Hence, it may be the right time to invest in them for market-beating returns. Keep reading.

StockNews.com

Biogen Whale Trades For October 20

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades.

Benzinga

This Is What Whales Are Betting On Biogen

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

2 Top Biotech Stocks to Buy for the Long Haul and 1 to Sell

Government initiatives to expand domestic biotech production and research and rising private investments in advancing technologies are expected to boost the industry’s prospects. While we believe biotech stocks Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) could be ideal investments for the long run, fundamentally weak Timber Pharmaceuticals (TMBR) might be best…

StockNews.com

2 Stocks with Great Track Records to Buy Right Now

Despite the Fed's aggressive interest rate hikes, the job market remains strong. However, given the mounting recessionary fears, it may be prudent to invest in UnitedHealth Group (UNH) and Biogen (BIIB), based on their solid fundamentals and impressive growth prospects. Continue Reading….

StockNews.com

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

StockNews.com

3 Biotech Stocks That'll Make You Richer and 1 That Won't

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga

Check Out What Whales Are Doing With BIIB

A whale with a lot of money to spend has taken a noticeably bullish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 19 strange trades.

Benzinga

Looking At Biogen's Recent Whale Trades

Benzinga

Biogen Whale Trades For September 14

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What Are Whales Doing With Biogen

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 28 strange trades.

StockNews.com

4 Stocks You’ll Be Glad You Bought

The recent rally in the benchmark indices indicates improving investors’ sentiments. Moreover, analysts believe the economy could likely dodge a recession. So, it could be wise to consider buying quality stocks CVS Health (CVS), APA (APA), Biogen (BIIB), and Centene (CNC) now. Keep reading….

StockNews.com

5 Biotech Stocks to Buy and Hold for the Next Decade

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

Benzinga

Biogen Whale Trades Spotted

Benzinga

Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of $31.20 billion.

StockNews.com

3 Biotech Stocks to Buy Now

Biotech stocks are starting to move higher as longer-term rates decline. The sector is very cheap with strong long-term fundamentals. Amgen (AMGN), Biogen (BIIB), and Bio-Techne (TECH) are 3 top biotech stocks that investors should consider buying.

Benzinga

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Microsoft Corporation

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.